20207-16-3

Usage

Uses

Ethyl 2-amino-3-oxobutanoate, HCl

Upstream product

• 5408-04-8 ethyl 2-hydroxyimino-3-oxobutanoate 
• 51026-98-3 ethyl 2-nitro-3-oxobutyrate 
• 66508-94-9 2-[(E)-hydroxyimino]-3-oxobutyric acid ethyl ester 
• 178200-66-3 (2RS)-tert-butoxycarbonylamino-3-oxo-butyric acid ethyl ester 
• 141-97-9 ethyl acetoacetate 

Downstream Products

• 77335-93-4 ethyl 5-methyl-2-phenyl-1H-imidazole-4-carboxylate 
• 61151-96-0 ethyl 5-methyl-2-phenyloxazole-4-carboxylate 
• 5463-44-5 ethyl 3,5-dimethyl-4-nitropyrrole-2-carboxylate 
• 2436-79-5 diethyl 2,4-dimethylpyrrole-3,5-dicarboxylate 
• 107367-58-8 3-Oxo-2-[(E)-3-(3-trifluoromethyl-phenyl)-acryloylamino]-butyric acid ethyl ester 
• 61151-95-9 2-cyclohexanecarbonylamino-3-oxo-butyric acid ethyl ester 
• 107367-57-7 2-[(E)-3-(2-Chloro-phenyl)-acryloylamino]-3-oxo-butyric acid ethyl ester 
• 123-32-0 2,5-dimethyl-pyrazine 
• 112381-11-0 ethyl 4-benzoyl-3-methylpyrrole-2-carboxylate 
• 858935-46-3 diethyl 3,3'-dimethyl-4,4'-dibenzoyl-5,5'-dipyrrolylmethane-2,2'-dicarboxylate 
• 500890-03-9 ethyl 2,4-dimethyl-1H-imidazole-5-carboxylate 
• 554-68-7 triethylamine hydrochloride 
• 146650-89-7 ethyl 5-methyl-2-propyl-3H-imidazole-4-carboxylate 
• 1434874-14-2 C₂₀H₂₇N₃O₄ 

Relevant academic research and scientific papers

OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS

The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE

The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in inter alia cancer is disclosed.

INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE

The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in inter alia the treatment of cancer is disclosed. Formula (I)

OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

OXAZOLE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

OXAZOLE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Synthesis and structure-activity relationships of novel zwitterionic compounds as peroxisome proliferator activated receptor α/γ dual agonists with improved physicochemical properties

We describe herein the design, syntheses and structure-activity relationships (SAR) of novel zwitter-ionic compounds as non-thiazolidinedion (TZD) based peroxisome proliferator activated receptor (PPAR) α/γ dual agonists. In the previous report, we obtained compound 1 showing potent PPARα/γ dual agonistic activities, together with a great glucose lowering effect in the db/db mice. However, this compound possessed fatal issues such as potent cytochrome P450 (CYP)3A4 direct inhibitory activity. Thus, we carried out the medicinal optimization to improve these while maintaining the potent PPAR agonistic activity. As a result, the issues were addressed by changing the furan ring to a low lipophilic 1,3,4-oxadiazole ring. Additionally, these oxadiazole derivatives exhibited a significant decrease in plasma glucose and plasma triglyceride levels without marked weight gain.

3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES

The invention relates to 3-aza-bicyclo[3.1.0]hexane derivatives of formula (I) wherein A, B, n, X, and R1 are as described in the description, and salts thereof, and their use as orexin receptor antagonists.

TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES

The invention relates to novel trans-3-aza-bicyclo[3.1.0]hexane derivatives of formula (I), wherein A, B, n and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.

2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES

The invention relates to novel 2-aza-bicyclo[3.1.0]hexane derivatives of Formula (I) wherein A, B, n and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.